细胞外囊泡组织因子活性测定
2023年12月29日
1.5K 次观看
在这里，我们描述了一种内部细胞外囊泡组织因子活性测定。基于活性的测定和基于抗原的测定已被用于测量人血浆样品中细胞外囊泡中的组织因子。与基于抗原的检测相比，基于活性的检测具有更高的灵敏度和特异性。
不同疾病患者的血浆中存在低水平的组织因子阳性细胞外囊泡。然而，大多数基于抗原的检测方法，包括 ELISA 和流式细胞术，不具备检测这些低水平的灵敏度。许多论文采用ELISA或流式细胞术来检测血浆中的组织因子。
我们的方案以高灵敏度和特异性测量血浆中的组织因子活性，尽管由于使用功能测定而存在一些变异性。有商业检测试剂盒可以测量血浆中组织因子活性的水平。然而，这些试剂盒不含抗组织因子抗体，因此无法区分组织因子依赖性和组织因子非依赖性因子 X 生成。
查看完整文字稿并访问数千部科学视频
概述
本文介绍了一种用于测量来自人血浆的细胞外囊泡中的组织因子活性的内部检测方法。该检测方法比传统的基于抗原的方法具有更高的灵敏度和特异性。
关键研究组成部分
科学领域
- 神经科学
- 生物学
背景
- 在各种疾病的血浆中发现了低水平的组织因子阳性细胞外囊泡。
- 像ELISA和流式细胞术这样的基于抗原的检测方法通常缺乏所需的灵敏度。
- 现有的商业试剂盒不能区分组织因子依赖和独立的X因子生成。
研究目的
- 用改进的灵敏度和特异性测量血浆中的组织因子活性。
- 提供一种能够检测低水平组织因子的功能性检测方法。
- 解决当前基于抗原的检测方法的局限性。
使用的方法
- 内部细胞外囊泡组织因子活性检测方法。
- 活性基和抗原基检测方法的比较。
- 检测组织因子的灵敏度和特异性评估。
- 功能性检测结果的变异性分析。
主要结果
- 活性基检测方法比抗原基检测方法显示出更高的灵敏度。
- 功能性检测方法成功检测到血浆中的低水平组织因子。
- 由于功能性检测的性质，结果中存在变异性。
- 商业试剂盒被发现不足以区分组织因子活性。
结论
- 内部检测方法提供了一种可靠的测量组织因子活性的方法。
- 它比传统的基于抗原的检测方法有显著改进。
- 该方法可以增强对组织因子在各种疾病中作用的理解。
常见问题
什么是组织因子？
组织因子是一种启动血液凝结的蛋白质，存在于细胞外囊泡中。
为什么基于抗原的检测方法不够？
它们通常缺乏检测血浆样本中低水平组织因子的灵敏度。
内部检测方法的优点是什么？
它提供了更高的灵敏度和特异性来检测组织因子活性。
该检测方法如何区分组织因子依赖和独立的活性？
内部检测方法旨在测量功能性活性，可以区分两者。
结果中存在什么变异性？
变异性可能来自于用于测量组织因子活性的检测方法的功能性质。
是否有商业试剂盒可用于这种测量？
有，但它们不包含抗组织因子抗体，并且在特异性方面存在局限性。
Executive Industry Relevance
Accurate quantification of tissue factor activity in extracellular vesicles is critical for de-risking thrombotic liability and understanding disease-associated coagulopathies in early drug discovery. The described activity-based assay enables sensitive and specific detection of TF-positive EVs, supporting mechanistic target validation and portfolio triage in indications where coagulation pathways are implicated. This capability enhances predictive confidence at the interface of discovery biology and translational research.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables functional interrogation of tissue factor activity in disease-relevant plasma samples.
- Supports biological de-risking by distinguishing TF-dependent from TF-independent FXa generation.
- Improves predictive confidence for target validation in coagulation and inflammation pathways.
Screening & Assay Development
- Provides a validated, quantitative readout for EV-associated tissue factor activity.
- Facilitates assay standardization and reproducibility through use of a chromogenic substrate and standard curve.
- Enables reliable evaluation of compound effects on TF activity in screening campaigns.
Translational & Preclinical Research
- Aligns with translational biomarker strategies by quantifying TF-positive EVs linked to disease severity.
- Supports continuity from discovery through preclinical validation in models of thrombosis and coagulopathy.
- De-risks advancement decisions by providing mechanistic evidence of TF activity modulation.
Pipeline & Workflow Integration
This activity assay integrates into the discovery-to-preclinical continuum, enabling hypothesis testing, target validation, and translational biomarker alignment for coagulation-related programs.
- Discovery Biology: Supports mechanistic hypothesis testing and clarifies TF pathway involvement in disease models.
- Screening: Delivers quantitative, reproducible outputs for compound screening and assay development.
- Analytics: Provides sensitive FXa generation measurements and statistical discrimination of TF-dependent activity.
- Translational Research: Bridges discovery findings to preclinical biomarker strategies in thrombotic risk assessment.
- Enterprise Reuse: Offers a reusable platform for functional EVTF activity measurement across multiple programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in TF-related target validation.
- Operational Value: Enhances assay standardization, reproducibility, and scalability for cross-program use.
- Strategic Value: Informs go/no-go decisions and reduces late-stage biological risk in coagulation-focused portfolios.
- Portfolio Impact: Enables risk-adjusted prioritization and advancement of assets with TF pathway involvement.
Implementation Considerations
- Requires expertise in coagulation biology and functional assay development.
- Needs access to plate readers, centrifugation infrastructure, and validated reagents.
- Demands cross-team standardization for reproducibility and data comparability.
- May require adaptation for different plasma sources or disease models.
- Functional assay variability should be managed through rigorous controls and standard curves.
Biopharma FAQs
Why does null hypothesis testing matter for FXa generation assays?
Null hypothesis testing in FXa generation assays enables teams to distinguish true TF-dependent activity from background or TF-independent effects, supporting robust target validation and reducing false positives in early discovery.
How does anti-TF antibody isolation fit the discovery pipeline?
Inclusion of anti-TF antibody controls allows isolation of TF-dependent FXa generation, clarifying mechanistic contributions and informing target confidence during the discovery and validation phases.
What do quantitative chromogenic substrate measurements enable?
Quantitative chromogenic substrate readouts provide sensitive, reproducible measurement of FXa levels, enabling reliable comparison of TF activity across samples and supporting data-driven decision making in assay development.
Why are replication requirements critical for cross-functional collaboration?
Replication of the EVTF activity assay ensures data reliability and comparability across teams, facilitating cross-functional collaboration and alignment on mechanistic findings and advancement decisions.
What statistical analysis is required before implementing FXa readouts?
Statistical analysis of FXa readouts, including use of standard curves and controls, is essential to validate assay sensitivity, specificity, and reproducibility before integrating results into portfolio decision workflows.
